Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension.
暂无分享,去创建一个
M. Böhm | E. Erdmann | S. Schirmer | U. Hoppe | F. Mahfoud | M. Brandt | S. Reda | M. Böhm
[1] H. Krum,et al. Sympatho-renal axis in chronic disease , 2011, Clinical Research in Cardiology.
[2] H. Krum,et al. Effect of Renal Sympathetic Denervation on Glucose Metabolism in Patients With Resistant Hypertension: A Pilot Study , 2011, Circulation.
[3] H. Krum,et al. Device-Based Antihypertensive Therapy: Therapeutic Modulation of the Autonomic Nervous System , 2011, Circulation.
[4] M. Volpe,et al. [The progression from hypertension to congestive heart failure]. , 2011, Recenti progressi in medicina.
[5] H. Krum,et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial , 2010, The Lancet.
[6] F. Cuccurullo,et al. RELATIONSHIP BETWEEN METABOLIC SYNDROME AND LEFT VENTRICULAR REMODELING: INFLUENCE OF GENDER: PP.22.356 , 2010, American journal of hypertension.
[7] A. M. Leone,et al. Why beta-blockers should not be used as first choice in uncomplicated hypertension. , 2010, The American journal of cardiology.
[8] E. Muxfeldt,et al. Prognostic impact of baseline and serial changes in electrocardiographic left ventricular hypertrophy in resistant hypertension. , 2010, American heart journal.
[9] J. S. Janicki,et al. Sympathetic Nervous System Modulation of Inflammation and Remodeling in the Hypertensive Heart , 2010, Hypertension.
[10] W. J. Elliott,et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study , 2010 .
[11] H. Krum,et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. , 2009, The New England journal of medicine.
[12] G. Mancia,et al. Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure values , 2009, Journal of hypertension.
[13] Arturo Evangelista,et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. , 2009, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[14] L. Ruilope,et al. Left ventricular hypertrophy and clinical outcomes in hypertensive patients. , 2008, American journal of hypertension.
[15] A. Pose-Reino,et al. Deberían los bloqueadores beta permanecer en la primera línea del tratamiento de la hipertensión arterial esencial , 2007 .
[16] Alice Stanton,et al. Differential Impact of Blood Pressure–Lowering Drugs on Central Aortic Pressure and Clinical Outcomes: Principal Results of the Conduit Artery Function Evaluation (CAFE) Study , 2006, Circulation.
[17] Richard B Devereux,et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[18] G. Palladini,et al. Sympathectomy or Doxazosin, But Not Propranolol, Blunt Myocardial Interstitial Fibrosis in Pressure-Overload Hypertrophy , 2005, Hypertension.
[19] L. Lindholm,et al. Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis , 2005, The Lancet.
[20] R. Devereux,et al. Cardiovascular Morbidity and Mortality in Hypertensive Patients With Lower Versus Higher Risk: A LIFE Substudy , 2005, HYPERTENSION.
[21] M. Nieminen,et al. Prognostic significance of left ventricular mass change during treatment of hypertension. , 2004, JAMA.
[22] M. Nieminen,et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. , 2004, JAMA.
[23] F. Magrini,et al. Different Effects of Antihypertensive Therapies Based on Losartan or Atenolol on Ultrasound and Biochemical Markers of Myocardial Fibrosis: Results of a Randomized Trial , 2004, Circulation.
[24] R. Schmieder,et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. , 2003, The American journal of medicine.
[25] Douglas W Mahoney,et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. , 2003, JAMA.
[26] Arantxa González,et al. Losartan-Dependent Regression of Myocardial Fibrosis Is Associated With Reduction of Left Ventricular Chamber Stiffness in Hypertensive Patients , 2002, Circulation.
[27] M. Nieminen,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[28] P. Weidmann,et al. Diastolic dysfunction precedes myocardial hypertrophy in the development of hypertension. , 2001, American journal of hypertension.
[29] R. Devereux,et al. Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population : the LIFE study. , 2000, Hypertension.
[30] G. Grassi,et al. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. , 1999, Hypertension.
[31] S. Vatner,et al. β-Adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic Gsα mouse , 1999 .
[32] S. Vatner,et al. Beta-adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic G(salpha) mouse. , 1999, The Journal of clinical investigation.
[33] G. Dibona,et al. Neural control of renal function. , 1997, Physiological reviews.
[34] N. Chang,et al. Patterns of isolated septal hypertrophy and their clinical correlations in essential hypertension , 1996 .
[35] G. Schillaci,et al. Asymmetric left ventricular remodeling due to isolated septal thickening in patients with systemic hypertension and normal left ventricular masses. , 1994, The American journal of cardiology.
[36] W. Kannel,et al. Left ventricular hypertrophy as a risk factor in arterial hypertension. , 1992, European heart journal.
[37] K. Pennert,et al. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. , 1992, American journal of hypertension.
[38] J. Laragh,et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. , 1991, Annals of internal medicine.
[39] B. Tallant,et al. Hypertrophy, fibrosis and diastolic dysfunction in early canine experimental hypertension. , 1991, Journal of the American College of Cardiology.
[40] D. Levy,et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. , 1990, The New England journal of medicine.
[41] R. O’rahilly,et al. Book ReviewNeuroanatomy: An atlas of structures, sections and systems , 1987 .
[42] Mosteller Rd. Simplified Calculation of Body-Surface Area , 1987 .
[43] N. Reichek,et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. , 1986, The American journal of cardiology.
[44] B. Massie,et al. Abnormal left ventricular filling: an early finding in mild to moderate systemic hypertension. , 1984, The American journal of cardiology.